Abstract
The current study aims to report the frequency and therapy used for treating symptoms associated with conjunctivitis in confirmed COVID-19 patients in clinical practice since the appearance of the virus. As materials and methods, a systematic review protocol was developed based on the Prisma statement. Also, articles for review were identified using Google Scholar, Medline (Pubmed), Embase, and Web of Science. The bibliographic search identified 2815 results. After complete reading, 14 articles were selected since they included information on the frequency of symptoms associated with conjunctivitis in positive patients for COVID-19. 8 case reports, 4 case series, and 2 cross-sectional studies were analyzed, of which 8 (57.14%) studies reported ocular treatment. The frequency of conjunctivitis in confirmed COVID-19-positive patients in respiratory and tear samples was 52/865 (6.01%). In contrast, corneal involvement was related to superficial punctate keratitis and pseudodendrites, only in 2/865 (0.23%) patients. The experience in the clinical approach has been examined with oral and topical antivirals (vanciclovir, ganciclovir, ribavirin), ocular lubricants, and topical antibiotics (moxifloxacin), with the resolution of symptoms and absence of subsequent complications.References
Coroneo MT. The eye as the discrete but defensible portal of coronavirus infection. Ocul Surf. 2020;19: 176-182. Disponible en: http://dx.doi.org/10.1016/j.jtos.2020.05.011
Willcox MDP, Walsh K, Nichols JJ, Morgan PB, Jones LW. The ocular surface, coronaviruses and COVID-19. Clin Exp Optom. 2020;103(4): 1-7. Disponible en: http://dx.doi.org/10.1111/cxo.13088
Peng Y, Zhou YH. Is novel coronavirus disease (COVID-19) transmitted through conjunctiva? J Med Virol. 2020;92(9): 19-20. Disponible en: http://dx.doi.org/10.1002/jmv.25753
Hu Y, Chen T, Liu M, Zhang L, Wang F, Zhao S, et al. Positive detection of SARS-CoV-2 combined HSV1 and HHV6B virus nucleic acid in tear and conjunctival secretions of a non-conjunctivitis COVID-19 patient with obstruction of common lacrimal duct. Acta Ophthamol. 2020;98(8): 1-5. Disponible en: http://dx.doi.org/10.1111/aos.14456
Karimi S, Arabi A, Shahraki T, Safi S. Detection of severe acute respiratory syndrome Coronavirus-2 in the tears of patients with Coronavirus disease 2019. Eye. 2020;34: 1220-1223. Disponible en: https://dx.doi.org/10.1038/s41433-020-0965-2
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18): 1708-1720. Disponible en: http://dx.doi.org/10.1056/NEJMoa2002032
Almazroa A, Alamri S, Alabdulkader B, Alkozi H, Khan A, et al. Ocular transmission and manifestation for coronavirus disease: a systematic review. Inter Hea. 2022;14(2): 131-121. Disponible en: https://doi.org/10.1093/inthealth/ihab028
Qu JY, Xie HT, Zhang MC. Evidence of SARSCoV-2 Transmission Through the Ocular Route. Clin Ophthalmol. 2021;15: 687-696. Disponible en: https://doi.org/10.2147/OPTH.S295283
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1): 1. Disponible en: https://doi.org/10.1186/2046-4053-4-1
Cheema M, Aghazadeh H, Nazarali S, Ting A, Hodges J, McFarlane A, et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19). Can J Ophthalmol. 2020;55(4): E125-E129. Disponible en: http://dx.doi.org/10.1016/j.jcjo.2020.03.003
Loffredo L, Pacella F, Pacella E, Tiscione G, Oliva A, Violi F. Conjunctivitis and COVID-19: A metaanalysis. J Med Virol. 2020;92(9): 1413-1414. Disponible en: http://dx.doi.org/10.1002/jmv.25938
Ulhaq ZS, Soraya GV. The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/fluid. Graef Arch Clin Exp Ophthalmol. 2020;258(6): 1351-1352. Disponible en: http://dx.doi.org/10.1007/s00417-020-04695-8
Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2): 631-637. Disponible en: http://dx.doi.org/10.1002/path.1570
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2): p271-280.e8. Disponible en: http://dx.doi.org/10.1016/j.cell.2020.02.052
Chandra S, Flanagan D, Hingorani M, Lotery A, Sivaprasad S. COVID19 and ophthalmology: a brief summary of the literature. Eye. 2020;34: 1200-1202. Disponible en: http://dx.doi.org/10.1038/s41433-020-0956-3
Navel V, Chiambaretta F, Dutheil F. Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2. Am J Ophthalmol Case Reports. 2020;19: 100735. Disponible en: http://dx.doi.org/10.1016/j.ajoc.2020.100735
Chen YY, Yen YF, Huang LY, Chou P. Manifestations and Virus Detection in the Ocular Surface of Adult COVID-19 Patients: A Meta-Analysis. J Ophthalmol. 2021;2021: 9997631. Disponible en: http://dx.doi.org/10.1155/2021/9997631
Wu P, Liang L, Chen CB, Nie SQ. A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis. Graef Arch Clin Exp Ophthalmol. 2020;258: 19-20. Disponible en: http://dx.doi.org/10.1007/s00417-020-04708-6
Sen M, Honavar SG, Sharma N, Sachdec MS. COVID-19 and Eye. A Review of Ophthalmic Manifestations of COVID-19. Ind Jour Ophthal. 2021;69(3): 488-509. Disponible en: http://dx.doi.org/10.4103/ijo.IJO_297_21
Konjevoda S, Canovic S, Pastar Z, Tabain I, Savic V, Barbic L, et al. Ophthalmic manifestations of novel coronaviruses: precautionary measures and diagnostic possibilities. J Glob Health. 2020;10(1): 1-4. Disponible en: http://dx.doi.org/10.7189/JOGH.10.010340
Conde Y, Puente Gete B, Gil Ibáñez L, Esquivel Benito G, Asencio Duran M, Dabad Moreno JV. Pandemia COVID-19: impacto sobre la tasa de conjuntivitis virales. Arch Soc Esp Oftalmol. 2022;97(2): 63-69. Disponible en: http://dx.10.1016/j.pftal.2021.03.002
Keywords
COVID-19
conjunctivitis
conjunctiva